Combinatorial approaches to the prevention and treatment of HIV-1 infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 1831-1842

  Pirrone, Vanessa ^a   Thakkar, Nina ^a   Jacobson, Jeffrey M ^a   Wigdahl, Brian ^a   Krebs, Fred C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ABACAVIR; ALPHA INTERFERON; AMPRENAVIR; ATAZANAVIR; ATEVIRDINE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MICROBICIDE; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SHORT SURVEY; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; VIRUS PARTICLE; VIRUS TRANSMISSION; WEIGHT GAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV-1; HUMANS;

EID: 79955542814     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00976-10     Document Type: Short Survey

References (108)

1. Ahluwalia, G., et al. 1987. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36:3797-3800.
2. AIDS Clinical Trials Group. 1993. Executive summary for ACTG 155. AIDS Clinical Trials Group, Bethesda, Maryland.
3. Allaway, G. P., et al. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11:533-539.
4. Allendoerfer, R., A. J. Marquis, M. G. Rinaldi, and J. R. Graybill. 1991. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 35:726-729.
5. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
6. Baba, M., et al. 1999. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 96:5698-5703.
7. Balzarini, J., et al. 1998. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 12:1129-1138. (Pubitemid 28302414)
8. Balzarini, J., and L. Van Damme. 2007. Microbicide drug candidates to prevent HIV infection. Lancet 369:787-797. (Pubitemid 46335821)
9. Barchiesi, F., et al. 1998. In vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59-65.
10. Barchiesi, F., et al. 1999. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J. Antimicrob. Chemother. 44:65-70.
11. Barnard, J., G. Borkow, and M. A. Parniak. 1997. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36:7786-7792.
12. Berger, A. R., et al. 1993. 2′,3′-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 43:358-362. (Pubitemid 23060270)
13. Bliss, C. I. 1939. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26:585-615.
14. Bolmstedt, A. J., B. R. O'Keefe, S. R. Shenoy, J. B. McMahon, and M. R. Boyd. 2001. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol. Pharmacol. 59:949-954.
15. Boyd, M. R., et al. 1997. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41:1521-1530.
16. Burton, D. R., and C. F. Barbas, 3rd. 1994. Human antibodies from combinatorial libraries. Adv. Immunol. 57:191-280.
17. Burton, D. R., and C. F. Barbas III. 1994. Human monoclonal antibodies: recent achievements. Hosp. Pract. (Off. ed.) 29:111, 114-116, 119 passim.
18. Caliendo, A. M., and M. S. Hirsch. 1994. Combination therapy for infection due to human immunodeficiency virus type 1. Clin. Infect. Dis. 18:516-524.
19. Campbell, T. B., et al. 1993. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U- 87201E) in combination with zidovudine or didanosine. J. Infect. Dis. 168: 318-326.
20. Cheeseman, S. H., et al. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:141-151.
21. Chen, I. J., N. Neamati, and A. D. MacKerell, Jr. 2002. Structure-based inhibitor design targeting HIV-1 integrase. Curr. Drug Targets Infect. Disord. 2:217-234.
22. Chou, K. C. 1980. A new schematic method in enzyme kinetics. Eur. J. Biochem. 113:195-198.
23. Chou, T. C., and P. Talalay. 1983. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 4:450-454.
24. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
25. Clay, P. G. 2004. Single-class therapy for HIV is not optimal care. Ann. Pharmacother. 38:1307-1309.
26. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
27. Cohen, J. 14 December 2009, posting date. HIV outwits yet another microbicide. Sci. Now. http://news.sciencemag.org/sciencenow/2009/12/14-01.html? ref=hp.
28. Collier, A. C., et al. 1993. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann. Intern. Med. 119:786-793.
29. Dorr, P., et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
30. Dragic, T., et al. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 97:5639-5644.
31. Dueweke, T. J., et al. 1993. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37: 1127-1131.
32. Eron, J. J., Jr, V. A. Johnson, D. P. Merrill, T. C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro. Antimicrob. Agents Chemother. 36:1559-1562.
33. Esser, M. T., et al. 1999. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73:4360-4371. (Pubitemid 29189883)
34. Fang, W., et al. 2009. Poly(styrene-alt-maleic anhydride) derivatives as potent anti-HIV microbicide candidates. Bioorg. Med. Chem. Lett. 19: 1903-1907.
35. Fatkenheuer, G., et al. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11:1170-1172.
36. Fernandez-Romero, J. A., et al. 2007. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex. Transm. Dis. 34:9-14.
37. Finney, D. J. 1942. The analysis of toxicity tests on mixtures of poisons. Ann. Appl. Biol. 29:82-94.
38. Fischl, M. A., et al. 1993. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann. Intern. Med. 118:762-769.
39. Furuta, R. A., C. T. Wild, Y. Weng, and C. D. Weiss. 1998. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:276-279.
40. Gantlett, K. E., J. N. Weber, and Q. J. Sattentau. 2007. Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res. 75:188-197.
41. Gerstoft, J., et al. 2003. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 17:2045-2052. (Pubitemid 37297152)
42. Goldin, A., and N. Mantel. 1957. The employment of combinations of drugs in the chemotherapy of neoplasia: a review. Cancer Res. 17:635-654.
43. Goldman, M. E., et al. 1991. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U. S. A. 88:6863-6867.
44. Gulick, R. M., et al. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
45. Halpern, V., et al. 2008. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One 3:e3784.
46. Hicks, C., and R. M. Gulick. 2009. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 48:931-939.
47. Hirsch, M. S., et al., for the International AIDS Society - USA Panel. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:1984-1991.
48. Huff, B. 2006. Something new under the sun. Maraviroc poised for approval. GMHC Treat. Issues 20:1-4.
49. Jacobson, J. M., et al. 2000. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:326-329.
50. Johnson, V. A., et al. 1991. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. 164:646-655.
51. Ketas, T. J., et al. 2003. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res. Hum. Retroviruses 19:177-186.
52. Kilby, J. M., et al. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
53. Lederman, M. M., R. E. Offord, and O. Hartley. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6:371-382.
54. Liu, S., H. Lu, A. R. Neurath, and S. Jiang. 2005. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 49:1830-1836.
55. Liu, Y., Y. Y. Zhu, G. Wei, and W. Y. Lu. 2009. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: Improved in vitro and in vivo sustained-release properties. Eur. J. Pharm. Sci. 37:306-312.
56. Loewe, S. 1957. Antagonisms and antagonists. Pharmacol. Rev. 9:237-242.
57. Loewe, S. 1953. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285-290.
58. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
59. Martinez-Irujo, J. J., M. L. Villahermosa, E. Alberdi, and E. Santiago. 1996. A checkerboard method to evaluate interactions between drugs. Biochem. Pharmacol. 51:635-644.
60. Meek, T. D. 1992. Inhibitors of HIV-1 protease. J. Enzyme Inhib. 6:65-98.
61. Merluzzi, V. J., et al. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413. (Pubitemid 120031860)
62. Microbicide Trials Network. 2009. MTN fact sheet: HPTN 035 at a glance. Microbicide Trials Network, Pittsburgh, PA. http://www.mtnstopshiv.org /news/studies/hptn035/facts.
63. Microbicide Trials Network. 2009. Trial finds microbicide promising as HIV prevention method for women. Microbicide Trials Network, Pittsburgh, PA. http://www.mtnstopshiv.org/node/765.
64. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy- associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. U. S. A. 83:1911-1915.
65. Mori, T., and M. R. Boyd. 2001. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4- independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob. Agents Chemother. 45:664-672.
66. Moyle, G. J. 1997. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J. Antimicrob. Chemother. 40: 765-777.
67. Nagashima, K. A., et al. 2001. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:1121-1125.
68. Najera, I., et al. 1995. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31. (Pubitemid 24378774)
69. Najera, I., et al. 1994. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses 10:1479-1488.
70. Neurath, A. R., N. Strick, S. Jiang, Y. Y. Li, and A. K. Debnath. 2002. Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect. Dis. 2:6.
71. Neurath, A. R., N. Strick, and Y. Y. Li. 2006. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect. Dis. 6:150.
72. Neurath, A. R., N. Strick, Y. Y. Li, and A. K. Debnath. 2001. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect. Dis. 1:17.
73. Olson, W. C., et al. 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73:4145-4155. (Pubitemid 29189860)
74. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentsGL.pdf.
75. Pirrone, V., et al. 2010. A styrene-alt-maleic acid copolymer is an effective inhibitor of R5 and X4 human immunodeficiency virus type 1 infection. J. Biomed. Biotechnol. 2010:548749.
76. Pluymers, W., E. De Clercq, and Z. Debyser. 2001. HIV-1 integration as a target for antiretroviral therapy: a review. Curr. Drug Targets Infect. Disord. 1:133-149.
77. Prasad, V. R., and S. P. Goff. 1990. Structure-function studies of HIV reverse transcriptase. Ann. N. Y. Acad. Sci. 616:11-21.
78. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
79. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. (Pubitemid 20377558)
80. Qian, J., et al. 2005. Use of the synthetic copolymer PSMA as a component in a combination microbicide active against HIV-1. Retrovirology 2(Suppl. 1):S96.
81. Richman, D. D., et al. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A doubleblind, placebo-controlled trial. N. Engl. J. Med. 317:192-197.
82. Richman, D. D., et al. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666. (Pubitemid 24065732)
83. Safarian, D., X. Carnec, F. Tsamis, F. Kajumo, and T. Dragic. 2006. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 352:477-484. (Pubitemid 44216012)
84. Schooley, R. T., et al. 1996. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:363-370.
85. Shiau, G. T., R. F. Schinazi, M. S. Chen, and W. H. Prusoff. 1980. Synthesis and biological activities of 5-(hydroxymethyl, azidomethyl, or aminomethyl)-2′-deoxyuridine and related 5′-substituted analogues. J. Med. Chem. 23:127-133.
86. Skoler-Karpoff, S., et al. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987.
87. Smith, D. H., et al. 1987. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238:1704-1707. (Pubitemid 18046271)
88. Sondak, V. K., E. L. Korn, and D. H. Kern. 1988. In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int. J. Cell Cloning 6:378-391.
89. Sondak, V. K., E. L. Korn, D. L. Morton, and D. H. Kern. 1988. Testing chemotherapeutic combinations in the human tumor colony-forming assay. J. Surg. Oncol. 37:156-160.
90. Strizki, J. M., et al. 2001. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:12718-12723.
91. Summa, V., et al. 2008. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51:5843-5855.
92. Tremblay, C., D. P. Merrill, T. C. Chou, and M. S. Hirsch. 1999. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. J. Acquir. Immune Defic. Syndr. 22:430-436.
93. Tremblay, C. L., et al. 2002. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46:1336-1339.
94. Tsai, C. C., et al. 2003. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 19:535-541.
95. Tsamis, F., et al. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77:5201-5208. (Pubitemid 36460934)
96. Van Damme, L., et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977. (Pubitemid 35284107)
97. van de Wijgert, J. H., et al. 2007. Carraguard vaginal gel safety in HIV-positive women and men in South Africa. J. Acquir. Immune Defic. Syndr. 46:538-546.
98. van Leeuwen, R., et al. 2003. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17:987-999.
99. van Moorsel, C. J., et al. 1999. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer. 80:981-990.
100. Veazey, R. S., et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346.
101. Veldstra, H. 1956. Synergism and potentiation with special reference to the combination of structural analogues. Pharmacol. Rev. 8:339-387.
102. Vermeire, K., et al. 2003. The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol. Pharmacol. 63:203-210.
103. Vermeire, K., et al. 2004. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 18:2115-2125. (Pubitemid 39463676)
104. Walker, D. K., et al. 2005. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33:587-595.
105. Warren, M., and K. Marshall. 2009. AVAC statement on MDP 301. Press release, 14 December 2009. AIDS Vaccine Advisory Coalition, New York, NY. http://www.hivvaccineenterprise.org/sites/default/files/avac%20statement %20on%20MPD%20301%20dec%2014.pdf.
106. Webb, J. L. 1963. Enzyme and metabolic inhibitors. Academic Press, New York, NY.
107. Woolley, D. W. 1952. A study of antimetabolites. Wiley, New York, NY.
108. Yarchoan, R., et al. 1988. Phase I studies of 2′,3′- dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1:76-81.